Characterization of new estrogen receptor destabilizing compounds: Effects on estrogen-sensitive and tamoxifen-resistant breast cancer

Journal of the National Cancer Institute

Volumn 96, Issue 3, 2004, Pages 210-218

  Hoffmann, Jens ^a   Bohlamann, Rolf ^a   Heinrich, Nikolaus ^a   Hofmeister, Helmut ^a   Kroll, Jörg ^a   Künzer, Hermann ^a   Lichtner, Rosemarie B ^a   Nishino, Yuki ^a   Parczyk, Karsten ^a   Sauer, Gerhard ^a   Gieschen, Hille ^a   Ulbrich, Hannes F ^a   Schneider, Martin R ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ANTIESTROGEN; DIMETHYLBENZ[A]ANTHRACENE; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; METHYLNITROSOUREA; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG; ZK 253; ZK 703;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; FEMALE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TUMOR RESISTANCE; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 10744226748     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh022     Document Type: Article

References (25)

1. Fisher B. From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century. Eur J Cancer 1999;35:1963-73.
2. Levenson AS, Jordan VC. Selective oestrogen receptor modulation: molecular pharmacology for the millennium. Eur J Cancer 1999;35:1974-85.
3. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, McInerney EM. William L. McGuire Memorial Lecture. Antiestrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 1997;44:23-38.
4. McDonnell DP, Connor CE, Wijayaratne A, Chang CY, Norris JD. Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. Recent Prog Horm Res 2002;57:295-316.
5. Curtis MG. Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention. Drug Saf 2001;24:1039-53.
6. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-8.
7. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol 2001;11:339-52.
8. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-73.
9. Wardley AM. Fulvestrant: a review of its development, pre-clinical and clinical data. Int J Clin Pract 2002;56:305-9.
10. Bohlmann R, Bittler D, Fritzemeier KH, Heinrich N, Hoffmann J, Hofmeister H, et al. Novel 7a-alkylamino substituted estradiol derivatives with pure antiestrogenic activity following oral administration. J Cancer Res Clin Oncol 2001;127:S42.
11. Clarke R. Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat 1996;39:69-86.
12. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973;51:1409-16.
13. Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Anal Biochem 1989;182:16-9.
14. Naundorf H, Fichtner I, Buttner B, Frege J. Establishment and characterization of a new human oestradiol- and progesterone-receptor-positive mammary carcinoma serially transplantable in nude mice. J Cancer Res Clin Oncol 1992;119:35-40.
15. Lichtner RB, Parczyk K, Birchmeier W, Schneider MR. Differential cross-talk of estrogen and growth factor receptors in two human mammary tumor cell lines. J Steroid Biochem Mol Biol 1999;71:181-9.
16. Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer 1996;74:300-8.
17. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746-50.
18. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403.
19. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-95.
20. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988;48:5183-7.
21. Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, Welch JN, et al. Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol 2001;76:71-84.
22. Labrie F, Labrie C, Belanger A, Simard J, Gauthier S, Luu-The V, et al. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol 1999;69:51-84.
23. Welsch CW. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res 1985;45:3415-43.
24. Huggins C, Yang NC. Induction and extinction of mammary cancer. A striking effect of hydrocarbons permits analysis of mechanisms of causes and cure of breast cancer. Science 1962;137:257-62.
25. Wilkinson JR, Williams JC, Singh D, Goss PE, Easton D, Coombes RC. Response of nitrosomethyl urea-induced rat mammary tumor to endocrine theraphy and comparison with clinical response. Cancer Res 1986;46:4862-5.